课题基金 / 基金详情

Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses

Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
了解受体酪氨酸激酶激活动力学如何指定增殖细胞反应
批准号:
10263909
负责人:
Mark A Lemmon
金额:
$52.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-15 至 2025-05-31

项目摘要

项目成果

Mark A Lemmon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary We propose to combine biophysical imaging and biochemical approaches to address two key unanswered questions in the field of signaling by receptor tyrosine kinases (RTKs) – a principal class of therapeutic targets in cancer where resistance to current therapies necessitates new pharmacological approaches: a. What defines the distinct set of responses, and cell fate, downstream of a particular RTK? b. How can different ligands for a given RTK promote distinct cellular responses? It is well known that epidermal growth factor (EGF) and nerve growth factor (NGF) promote proliferative and differentiative responses respectively in PC12 cells, through EGFR and TrkA, apparently using the same set of signaling pathways. Early studies showed that Erk activation kinetics plays a key role in determining the different cell fates induced by these ligands, with transient Erk activation being associated with proliferation and sustained Erk activation with differentiation. Rather than being defined solely by different feedback ‘wiring’ in the intracellular MAP kinase cascade, we and others have found that the RTK activation kinetics play a direct role in defining the dynamic properties of the signaling network. Several recent studies further argue that the strength of ligand-induced RTK dimers (and/or their lifetime) dictates signaling specificity, offering the possibility of dynamically-determined biased agonism in RTK signaling. To gain insight into the mechanistic basis for biased agonism in RTK signaling, we propose to elucidate how activating the same RTK intracellular region in different ways can result in dramatically different cellular responses (proliferation vs differentiation). Our previous structural, biophysical, and biochemical data suggest the hypothesis that signaling outcome is determined by RTK dimer stability and dynamics. Using intact and chimeric receptors, we will test this hypothesis by asking how altering RTK dimerization kinetics influences receptor endocytosis, post-endocytic trafficking, and dynamics of the downstream signaling network. We combine single-molecule imaging and microscopy studies of RTK trafficking with mass spectrometry and biochemical studies of downstream signaling networks to yield an integrated picture of this. Our primary motivation is to investigate how modifying RTK signaling dynamics (rather than simply inhibiting RTKs) might be used in future therapeutic approaches in cancer. Our Specific Aims address the following questions: 1 How can the same RTK intracellular region elicit orthogonal cellular responses depending on how it is activated? 2 What are the lifetimes of ErbB4/HER4 dimers induced by different neuregulin (NRG) ligands, and what is the basis for their sustained signaling? Our overall goal is to understand how dimerization dynamics can define signaling specificity, possibly through a kinetic proofreading similar to that seen in the T-cell receptor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
  • 批准号:
    10678825
  • 项目类别:
  • 资助金额:
    $51.82万
  • 财政年份:
    2020
  • 负责人:
    Mark A Lemmon
  • 依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
  • 批准号:
    10668978
  • 项目类别:
  • 资助金额:
    $35.71万
  • 财政年份:
    2020
  • 负责人:
    Mark A Lemmon
  • 依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
  • 批准号:
    10441508
  • 项目类别:
  • 资助金额:
    $35.43万
  • 财政年份:
    2020
  • 负责人:
    Mark A Lemmon
  • 依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
  • 批准号:
    10267847
  • 项目类别:
  • 资助金额:
    $35.71万
  • 财政年份:
    2020
  • 负责人:
    Mark A Lemmon
  • 依托单位:
海外基金